Skip to main content

Antares Pharma, Inc.

ATRSDelisted May 24, 2022
Industry
Surgical & Medical Instruments & Apparatus
SEC CIK
0001016169

Antares Pharma, Inc. was delisted on May 24, 2022; its insiders filed their last Form 4 on May 26, 2022; 177 institutions reported holding it in 13F filings for Q1 2022, worth $374.8M in total; no superinvestor held it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Antares Pharma, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Antares Pharma, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Antares Pharma, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Jacob Leonard SDirector0May 26, 20220
Apple Robert FPresident and CEO0May 26, 20220
Roche Robert P JrDirector0May 26, 20220
Graham Peter JSee Remarks0May 26, 20220
Gueth AntonDirector0May 26, 20220
Garrity Thomas JDirector0May 26, 20220
Volkart Carmen BDirector–May 26, 20220
Powell Fred MExecutive Vice President & CFO0May 26, 20220
Richardson Peter CSee Remarks0May 26, 20220
Greenleaf PeterDirector0May 26, 20220
Smith Karen L.Director0May 26, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jul 9, 2021 (view filing)Jul 81 dayGueth AntonDirectorSSale−100.0K$4.29−$429.0K−17.6%467.6K after